. Author manuscript; available in PMC: 2016 May 1.

Published in final edited form as: Int J Cancer. 2014 Oct 13;136(9):2166–2171. doi: 10.1002/ijc.29241

Table 2.

Hazard Ratios (HR) for Prostate Cancer-Specific Mortality Associated with a Panel of 22 SNPs in Two Patient Cohorts

Genetic Variants				Seattle Cohort				PROGRESS Cohort
SNP	Chr.	Gene	Alleles¹	MAF²	HR	95% CI	Model³	MAF²	HR	95% CI	P-value⁴	Model
rs1137100	1p31	LEPR	A/G	0.27	0.29	0.14–0.60	Dom: ACP	0.26	1.65	1.08–2.51	NC	Dom: ACP
rs228697	1p36	PER3	C/G	0.11	0.25	0.10–0.60	Dom: ACP	0.10	1.39	0.84–2.30	NC	Dom: ACP
rs635261	1q25	*RNASEL*	G/C	0.36	0.22	0.07–0.65	Rec: ACP	0.39	0.35	0.18–0.66	0.002	Rec: ACP
rs627839	1q25	RNASEL	G/T	0.47	3.98	1.64–9.65	Dom: ACP	0.48	0.83	0.56–1.21	NC	Dom: ACP
rs4583514	2p21	MSH2	G/A	0.38	2.49	1.21–5.10	Dom: ACP	0.38	0.68	0.45–1.03	NC	Dom: ACP
rs4608577	2p21	MSH2	T/G	0.17	2.04	1.36–3.07	Tre: A	0.17	1.09	0.77–1.55	0.33	Tre: ACP
rs523349	2p23	SRD5A2	C/G	0.29	0.49	0.28–0.86	Dom: A	0.29	1.08	0.71–1.67	NC	Dom: ACP
rs12467911	2p23	SRD5A2	C/T	0.28	0.45	0.24–0.81	Dom: A	0.30	1.14	0.75–1.72	NC	Dom: ACP
rs11710277	3p21	SEMA3F	A/G	0.09	3.71	1.75–7.90	Dom: ACP	0.06	0.75	0.39–1.42	NC	Dom: ACP
rs11205	5p23	HSD17B4	A/G	0.39	0.21	0.06–0.70	Rec: ACP	0.43	1.21	0.79–1.86	NC	Rec: A
rs2070874	5q31	IL4	C/T	0.16	2.16	1.27–3.67	Dom: A	0.16	1.17	0.80–1.72	0.25	Dom: A
rs1799964	6p21	TNF/LTA	T/C	0.21	0.39	0.20–0.77	Dom: A	0.22	1.19	0.82–1.72	NC	Dom: A
rs4645959	8q24	C-MYC	A/G	0.04	0	0.00–inf.	Tre: ACP	0.04	1.14	0.56–2.32	NC	Tre: ACP
rs1029153	10q11	CXCL12	T/C	0.31	0.22	0.07–0.75	Tre: A	0.29	1.14	0.87–1.51	NC	Tre: A
rs2839685	10q11	CXCL12	C/T	0.15	28.2	7.21–110.2	Rec: ACP	0.14	0.58	0.11–3.10	NC	Rec: A
rs2308327	10q26	MGMT	A/G	0.13	0.32	0.13–0.78	Tre: A	0.11	0.85	0.55–1.31	0.26	Tre: ACP
rs10778534	12q23	CRY1	T/C	0.36	2.21	1.19–4.12	Dom: A	0.36	0.68	0.45–1.03	NC	Dom: ACP
rs2494750	14q32	*AKT1*	C/G	0.07	0.22	0.07–0.70	Tre: ACP	0.05	0.45	0.23–0.90	0.016	Tre: A
rs1799814	15q24	CYP1A1	C/A	0.05	0.13	0.03–0.57	Tre: ACP	0.05	1.27	0.61–2.64	NC	Tre: ACP
rs25487	19q13	XRCC1	G/A	0.36	0.49	0.31–0.77	Tre: A	0.37	0.85	0.65–1.12	0.17	Tre: A
rs915927	19q13	*XRCC1*	A/G	0.43	2.54	1.24–5.18	Dom: A	0.41	1.91	1.21–3.02	0.009	Dom: ACP
rs5993891	22q11	ARVCF	C/T	0.05	0.21	0.07–0.61	Dom: ACP	0.05	1.53	0.91–2.57	NC	Dom: A

Major/minor allele.

MAF: minor allele frequency, calculated from cases who did not die of prostate cancer.

Model: Dom= dominant, Rec= recessive, Tre= trend; A= age at diagnosis, ACP= age plus clinicopathological covariates (i.e., Gleason score, diagnostic PSA, stage, and primary treatment).

⁴

NC: not confirmed (i.e., the direction of the HR in the PROGRESS confirmation cohort was in the opposite direction compared to the HR in the Seattle discovery cohort).